China Achieves Curie-Level Mass Production of Medical-Grade Alpha Isotopes: A Game-Changer for Cancer Treatment

The Institute of High Energy Physics (IHEP, Zhongguoxueyuan Gaoneng Wuli Yanjiusuo 中国科学院高能物理研究所) under the Chinese Academy of Sciences just dropped a major announcement.

Their flagship facility—the China Spallation Neutron Source (CSNS, Zhongguo Sanlie Zhongziyuan 中国散裂中子源)—has cracked the code on something the global medical community has been chasing for years.

They’ve achieved curie-level mass production of medical-grade alpha isotopes for the first time.

Here’s why this matters: China just broke free from decades of import dependency on life-saving cancer medicines.

The China Spallation Neutron Source (CSNS), the major scientific facility enabling curie-level mass production of medical-grade alpha isotopes.

---

What Are Alpha Isotopes? Understanding the Cancer-Fighting Technology

Before we dive into why this matters, let’s break down what makes alpha isotopes so special.

Alpha isotopes are a class of radioactive materials with a pretty unique superpower.

They have what researchers call a “high energy, short range” advantage.

Translation?

They pack enough punch to destroy cancer cells with surgical precision—while leaving healthy surrounding tissue largely untouched.

This makes them incredibly valuable for targeted therapy of mid-to-late-stage tumors, particularly in cases where traditional chemotherapy or radiation would cause too much collateral damage.

They’re essentially precision-guided missiles for your body’s cancer cells.

---

The Global Supply Problem That’s Been Plaguing Cancer Treatment

Here’s the catch: for decades, China—and most of the world—has been almost entirely dependent on imported alpha isotopes.

The most clinically important ones?

• Actinium-225 (Ac-225)
• Radium-223 (Ra-223)
• Lead-212 (Bismuth-212)

Global supply is scarce.

Manufacturing them at scale presents multiple technical barriers.

The result?

China’s domestic alpha nuclear medicine industry has been severely constrained, unable to develop the localized production capabilities needed to serve millions of patients.

This dependency meant higher costs, longer wait times, and limited access to cutting-edge cancer treatments.

---

How China Pulled Off This Medical Isotope Breakthrough

The CSNS team didn’t just stumble onto this solution.

Here’s the technical approach that made curie-level mass production possible:

The Production Method

• They tapped into extra beam flow from a high-energy, high-intensity linear accelerator
• Used that beam to irradiate stacked thorium targets
• Deployed a self-developed joint separation and purification process to extract the isotopes

The Results (July 2025)

In July 2025, the team achieved something significant: simultaneous extraction of high-purity Actinium-225, Radium-223, and Lead-212 (Bismuth-212) at the millicurie level.

Let’s break down what “high-purity” actually means here.

The radionuclide purity reached over 99%.

Labeling verification confirmed that the quality meets the standards of imported products.

In other words: China’s domestically produced isotopes are just as good as what they were importing before.

---

The Economic Impact: Breaking Import Dependency

This breakthrough does more than just solve a supply problem.

It establishes an economically viable localized production path for the first time.

After further process refinement, the facility has recently scaled up to achieve curie-level mass production of Lead-212 (Bismuth-212).

That’s a significant jump from millicurie to curie-level production—roughly a 1,000x increase in output.

---

The Next Phase: A Dedicated 300MeV Production Line

• Production Line: Dedicated 300MeV, 100kW facility
• Projected Capacity: Hundreds of curies per year
• Patient Impact: ~1,000,000 doses annually
• Total Investment: ¥200,000,000 RMB ($27.8M USD)

The Spallation Neutron Source Science Center isn’t stopping here.

They’re currently advancing construction of a dedicated 300MeV, 100kW alpha isotope production line.

Projected Capacity

Once operational, this facility will deliver:

• Annual production capacity of hundreds of curies
• Raw materials sufficient for nearly one million doses of nuclear medicine per year

Infrastructure Investment Required

Scaling this technology to industrial levels isn’t cheap.

Experts estimate infrastructure investments reaching approximately ¥200,000,000 RMB ($27,800,000 USD).

That’s a substantial bet on the future of Chinese cancer treatment.

---

Clinical Applications: Which Cancer Types Benefit Most?

Let’s talk about where these isotopes are actually being used in patient care.

Approved Applications

Radium-223 has already been approved for clinical treatment of bone-metastatic castration-resistant prostate cancer.

This is a specific but significant patient population—men with advanced prostate cancer that has metastasized to the bones.

Research & Development Applications

Actinium-225 and Lead-212 (Bismuth-212) have shown significant efficacy in targeted therapy research for:

• Mid-to-late-stage prostate cancer
• Neuroendocrine tumors

These are still primarily in the research phase, but the clinical promise is substantial.

---

What This Breakthrough Means for Chinese Patients & the Global Market

The mass production of these localized isotopes provides stable, reliable support for:

• Clinical research in China
• Patient care and access to advanced treatments
• Potential export opportunities as global demand for alpha isotopes continues to grow

For investors and founders watching the Chinese healthcare tech space, this is a reminder that breakthrough medical technology isn’t always about flashy biotech startups.

Sometimes it’s about patient investment in core scientific infrastructure—like the CSNS—that enables decades of innovation downstream.

China just proved it can domestically produce world-class medical-grade alpha isotopes.

That’s a competitive advantage that extends far beyond cancer treatment.

---

References

• China Realizes Curie-Level Production of Medical Alpha Isotopes – CCTV News (Yangshi Xinwen 央视新闻)
• Institute of High Energy Physics – Chinese Academy of Sciences (Zhongguoxueyuan Gaoneng Wuli Yanjiusuo 中国科学院高能物理研究所)
• Introduction to the China Spallation Neutron Source – CSNS
• Producing Actinium-225 for Cancer Treatment – International Atomic Energy Agency